Key result
Oral opioids lack established efficacy and safety evidence for refractory dyspnea in advanced heart failure.
Why the study?
Palliative opioids are needed for refractory dyspnea in advanced heart failure, but evidence on their efficacy and safety remains scarce and their use is not well established.
Does oral opioid therapy improve dyspnea and survival compared to intravenous/subcutaneous opioids in patients with advanced heart failure?
Does oral opioid therapy improve dyspnea and survival compared to intravenous/subcutaneous opioids in patients with advanced heart failure?
Oral low-dose opioids may be a practical and effective palliative treatment for refractory dyspnea in patients with advanced heart failure, potentially offering better survival to discharge than intravenous/subcutaneous administration.
No takes yet. Share an insight, caveat, or question.
Insufficient evidence supports oral opioids for refractory dyspnea in advanced HF; leaves open comparative benefits versus parenteral routes in palliative care.
Nakamura et al. (2023) studied this question. Oral opioid therapy for refractory dyspnea in advanced heart failure currently lacks established evidence regarding its efficacy and safety.